CytoDyn Inc.
CytoDyn Inc. (CYDY): 11 pipeline candidates · ~9 mo cash runway · 11 clinical trials. Updated within the last hour.
BioSniper Score
4-factor signal · derived from public data
9.0 months
D/E -1.18 · 0% dilution
Lead: Phase 2/Phase 3
11 candidates
N/A
N/A
A transparent, data-derived signal for CytoDyn Inc.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$380.4M
Cash
$15.7M
Quarterly Burn
$5.5M
Runway
9.0 mo
Revenue
—
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (11 candidates)
| Drug | Phase |
|---|---|
| 350 mg leronlimab | Phase 2 |
| 525 mg leronlimab | Phase 2 |
| 700 mg leronlimab | Phase 2 |
| Leronlimab | Phase 2 |
| Long-acting leronlimab | Phase 2 |
| Maximum Tolerated Dose of leronlimab | Phase 2 |
| PRO 140 | Phase 2/Phase 3 |
| PRO 140 350 | Phase 3 |
| PRO 140 350mg weekly subcutaneous injection. | Phase 2 |
| PRO 140 525 | Phase 3 |
Showing 10 of 11 candidates. Sign up for full pipeline.
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
8
Total value held
$75K
| Holder | Shares | Value |
|---|---|---|
| nbc securities, inc. | 160,000 | $44K |
| diversified trust co | 45,790 | $13K |
| next capital management llc | 25,000 | $7K |
| horizon financial services, llc | 18,200 | $5K |
| northstar asset management co | 10,000 | $3K |
| ancora advisors llc | 9,488 | $3K |
| caz investments lp | 4,000 | $1K |
| vsm wealth advisory, llc | 500 | $137 |
Frequently asked questions
How many drug candidates are in CytoDyn Inc.'s pipeline?
CytoDyn Inc. (CYDY) has 11 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is CytoDyn Inc.'s lead drug candidate?
CytoDyn Inc.'s most advanced tracked candidate is 350 mg leronlimab (Phase 2) for Metastatic Colorectal Cancer (mCRC); Triple Negative Breast Neoplasms.
What is CytoDyn Inc.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, CytoDyn Inc. has approximately 9.0 months of cash runway.
What is CytoDyn Inc.'s market capitalization?
CytoDyn Inc.'s market capitalization is approximately $380.4M.
Who is the CEO of CytoDyn Inc.?
Dr. Jacob P. Lalezari M.D. is the chief executive officer of CytoDyn Inc. (CYDY).
Get the full picture on CytoDyn Inc.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.